EFFECTS OF ARIPIPRAZOLE ON BRAIN MORPHOLOGY IN CONDUCT DISORDER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 破坏性行为障碍是一组儿童发病的精神疾病，其特征是外化行为，如冲动、言语和身体攻击以及犯罪(统称为行为问题)。阿立哌唑是一种新的非典型抗精神病药物，具有部分多巴胺(D2)受体激动剂活性。这项研究将收集冲动、犯罪和攻击性的临床测量，以及在基线和研究结束时获得的脑结构MRI扫描。这些研究人员希望找到基线前额叶皮质灰质体积与攻击严重程度之间的相关性。此外，他们还假设，在服用阿立哌唑的儿童中，攻击性行为的临床改善将与注意力缺陷多动障碍症状的减少密切相关。最后，他们预测在临床改善和前额叶腹侧容量测量变化之间存在关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Disruptive Behavior Disorders are a group of childhood-onset psychiatric conditions characterized by externalizing behaviors such as impulsivity, verbal and physical aggression, and delinquency (collectively referred to as conduct problems). Aripiprazole is a new atypical antipsychotic with a partial dopamine (D2) receptor agonist activity. This study will collect clinical measures of impulsivity, delinquency, and aggression as well as brain structural MRI scans obtained at baseline and at the end of the study. These investigators expect to find a correlation between baseline grey matter volume of ventral prefrontal cortices and severity of aggression. Furthermore, they hypothesize that clinical improvement in aggressive behavior will be strongly correlated with a reduction in attention deficit hyperactivity disorder symptomatology in children taking aripiprazole. Finally, they predict the presence of an association between clinical improvement and changes in ventral prefrontal volumetric measures.